Axsome Therapeutics Inc (AXSM.OQ)
AXSM.OQ on NASDAQ Stock Exchange Global Market
3.10USD
1:30am IST
3.10USD
1:30am IST
Change (% chg)
$0.10 (+3.33%)
$0.10 (+3.33%)
Prev Close
$3.00
$3.00
Open
$3.00
$3.00
Day's High
$3.10
$3.10
Day's Low
$3.00
$3.00
Volume
9,254
9,254
Avg. Vol
37,710
37,710
52-wk High
$6.45
$6.45
52-wk Low
$2.05
$2.05
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Buy | -0.29 | December | 21 Jun 2018 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 2 | 2 | 2 | 2 |
| (2) OUTPERFORM | 1 | 0 | 0 | 0 |
| (3) HOLD | 0 | 0 | 0 | 0 |
| (4) UNDERPERFORM | 0 | 0 | 0 | 0 |
| (5) SELL | 0 | 0 | 0 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 1.33 | 1.00 | 1.00 | 1.00 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 2 | 0.00 | 0.00 | 0.00 | 0.00 |
| Quarter Ending Sep-18 | 2 | 0.00 | 0.00 | 0.00 | 0.00 |
| Year Ending Dec-18 | 2 | 0.00 | 0.00 | 0.00 | 8.75 |
| Year Ending Dec-19 | 3 | 15.00 | 25.00 | 0.00 | 40.57 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 2 | -0.29 | -0.27 | -0.32 | -0.44 |
| Quarter Ending Sep-18 | 2 | -0.28 | -0.27 | -0.30 | -0.48 |
| Year Ending Dec-18 | 3 | -1.05 | -0.99 | -1.11 | -1.25 |
| Year Ending Dec-19 | 3 | -0.51 | -0.17 | -1.11 | -1.63 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Mar-18 | 0.00 | 0.00 | 0.00 | 0.00 |
| Quarter Ending Dec-17 | 0.00 | 0.00 | 0.00 | 0.00 |
| Quarter Ending Sep-17 | 0.00 | 0.00 | 0.00 | 0.00 |
| Quarter Ending Jun-17 | 0.00 | 0.00 | 0.00 | 0.00 |
| Quarter Ending Mar-17 | 0.00 | 0.00 | 0.00 | 0.00 |
| Earnings (per share) | ||||
| Quarter Ending Mar-18 | -0.28 | -0.19 | 0.09 | -32.14 |
| Quarter Ending Dec-17 | -0.31 | -0.31 | 0.00 | -1.59 |
| Quarter Ending Sep-17 | -0.34 | -0.27 | 0.07 | -20.59 |
| Quarter Ending Jun-17 | -0.34 | -0.30 | 0.04 | -10.90 |
| Quarter Ending Mar-17 | -0.39 | -0.41 | 0.02 | -5.13 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Quarter Ending Sep-18 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Year Ending Dec-18 | 0.00 | 0.00 | 0.00 | 10.00 | 8.75 |
| Year Ending Dec-19 | 15.00 | 15.00 | 22.50 | 12.50 | 40.57 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | -0.29 | -0.29 | -0.27 | -0.27 | -0.44 |
| Quarter Ending Sep-18 | -0.28 | -0.28 | -0.27 | -0.27 | -0.48 |
| Year Ending Dec-18 | -1.05 | -1.05 | -1.01 | -0.67 | -1.25 |
| Year Ending Dec-19 | -0.51 | -0.51 | -0.20 | -0.51 | -1.63 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Jun-18 | 0 | 0 | 0 | 0 |
| Quarter Ending Sep-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-19 | 0 | 0 | 0 | 0 |
| Earnings | ||||
| Quarter Ending Jun-18 | 0 | 0 | 0 | 0 |
| Quarter Ending Sep-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-19 | 0 | 0 | 0 | 0 |
Earnings vs. 
Estimates- BRIEF-Axsome Therapeutics Reports Q1 Loss Per Share Of $0.19
- BRIEF-Axsome Therapeutics Announces First Patient Enrolled In Phase 2 Clinical Trial Of AXS-05 In Smoking Cessation
- BRIEF-Axsome Therapeutics Appoints Nick Pizzie, Cpa, Mba, As Chief Financial Officer
- BRIEF-Axsome Therapeutics Reports Q4 Loss Per Share $0.31
- BRIEF-Axsome Therapeutics Says Its CNS Disorder Candidate AXS-09 Met Main Goal Of Phase 1 Trial